Home › Overweight › NCT07876531

A Study to Learn How Different Forms of the Study Medicine Called Berobenatide is Taken up Into the Blood in Adults With Overweight or Obesity

PHASE 1, SINGLE DOSE, OPEN-LABEL, RANDOMIZED, PARALLEL GROUP, PK COMPARABILITY STUDY BETWEEN DIFFERENT DELIVERY SYSTEMS OF BEROBENATIDE IN ADULTS WITH OVERWEIGHT OR OBESITY

Who can join

Ages 18 and older · All sexes · Healthy volunteers welcome

Key Inclusion Criteria:

* Participants 18 years of age or older
* BMI of 27-45 kg/m2; and a total body weight \>50 kg (110 lb)

Key Exclusion Criteria:

* Pregnant or breastfeeding women, or those planning pregnancy during the study
* History of other chronic disorders
* Personal or first-degree family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2), or suspected MTC
* Clinically significant gastric emptying abnormality or chronically taking drugs that directly affect gastrointestinal (GI) motility
* Acute GI symptoms at screening, Day -1, or prior to administration of study intervention

About the study

This is a single dose study to learn how safe and effective the study medicine is using different delivery systems for adults with overweight or obesity. Overweight or obesity means having more body fat than what is healthy.

The study involves multiple clinic visits at a study site over the length of the study.

What is being tested

• Berobenatide (drug)

Sponsor: Pfizer · Participants: 144 · Started: Oct 16, 2026

Contact the study team

• Pfizer CT.gov Call Center · Phone: 1-800-718-1021

Official record on ClinicalTrials.gov — NCT07876531

Locations in the U.S.

Conditions

• Overweight
• Obesity

From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.